Hypothesis

We propose that targeted epigenetic reinstatement of PRC2-mediated silencing at the CDKN2A/B locus in tissue‑resident macrophages is sufficient to suppress p16^INK4a‑driven SASP, thereby dampening inflammaging and extending healthspan independent of changes in other cell types.

Mechanistic Rationale

Age‑associated loss of EZH2 activity reduces H3K27me3 at the CDKN2A promoter, permitting ANRIL‑mediated chromatin opening and p16^INK4a transcription in macrophages [https://pmc.ncbi.nlm.nih.gov/articles/PMC3482262/]. Restoring EZH2 catalytic activity or recruiting PRC2 via CRISPR‑dCas9‑EZH2 fusion should re‑establish repressive marks, compact the locus, and lower p16^INK4a mRNA [https://doi.org/10.1101/2024.06.04.597161]. Lower p16^INK4a diminishes SASP cytokine output (IL‑6, CCL2) that otherwise fuels chronic inflammation and tissue fibrosis [https://www.pnas.org/doi/10.1073/pnas.1818313116].

Predictions & Experimental Design

1. In vitro: Bone‑marrow‑derived macrophages from old mice treated with dCas9‑EZH2 targeting the CDKN2A promoter will show >50% reduction in p16^INK4a mRNA (qPCR) and decreased SASP secretion (ELISA) compared with dCas9‑dead control [https://pmc.ncbi.nlm.nih.gov/articles/PMC3069667/].
2. Ex vivo: Adoptive transfer of edited macrophages into aged recipients will lower serum IL‑6 and improve grip strength after 4 weeks.
3. In vivo: Conditional EZH2 overexpression specifically in macrophages (Cx3cr1‑CreER; EZH2^fl‑STOP) in aged mice will extend median lifespan by ~15% and delay frailty index accumulation relative to littermate controls.
4. Falsifiability: If p16^INK4a reduction does not alter SASP or healthspan, the hypothesis that macrophage‑intrinsic CDKN2A/B drives inflammaging is falsified.

Potential Pitfalls

• Off‑target epigenetic effects of EZH2 overexpression could affect other senescence regulators; include ATAC‑seq to verify specificity.
• Macrophage plasticity may compensate via alternative inflammatory pathways; measure NF‑κB activity as a readout.
• Translating mouse findings to humans requires validation in primary human macrophages from young vs. old donors treated with EZH2‑activating small molecules [https://pubmed.ncbi.nlm.nih.gov/31270053/].

By focusing on a single immune cell type and a defined epigenetic node, this hypothesis tests whether fixing the 'armor' of the immune system can halt the village‑burning process of aging.